Pharmadefi SA
3.2 FTEThe score of Pharmadefi shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2025
Change 2022 → 2025: Equity +363 % Total assets -1 % Headcount (avg FTE) -32 %
Accounts of the company itself (not consolidated).
The full file covers 10 financial years; a free account shows 2. →Deterministic calculation on the filed accounts, no AI. Dispute the score or report an error
Pharmadefi's annual accounts
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net result | 158,135 € | ||||
| Equity | 671,836 € | ||||
| Cash | 28,628 € | ||||
| EBITDA | 421,188 € | ||||
| Total assets | €2.48m |
Filed annual accounts
- Year ended 31 Dec 2025filed on 20 Aug 2026
- Year ended 31 Dec 2024filed on 20 May 2025
- Year ended 31 Dec 2023filed on 19 Aug 2024
- Year ended 31 Dec 2022filed on 25 Jul 2023
- Year ended 31 Dec 2021filed on 18 Aug 2022
Pharmadefi's financial analysis
- Solvency27.1%sector median: 41.5%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of Pharmadefi
Pharmadefi's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 0437.576.896
- VAT number
- BE0437576896
- Peppol
- Registered · 0208:0437576896 · as of 09 Nov 2026
- Legal form
- SA
- Incorporated
- 29 May 1989
- Registered office
- 6700 Arlon
- Size
- Micro · 3.2 FTE
- Latest accounts
- 2025 · filed on 20 Aug 2026
- Activity
- Retail sale of pharmaceutical products (NACE 47730)
Pharmadefi (SA) has been based in Arlon since 1989, active in: retail sale of pharmaceutical products. For 2025, it reports a net profit of 158,135 € and equity of 671,836 €; its revenue is not published. With 3.2 full-time equivalents, it is a micro-enterprise by headcount. Its solvency stands at 27.1%, below the median of its sector (41.5%).
Companies similar to Pharmadefi
Companies in the same business, of comparable size and area, outside its group.
- Decon Retail sale of pharmaceutical products Maasmechelen · balance sheet €2.48m
- Apotheek Ducastel Retail sale of pharmaceutical products Wetteren · balance sheet €2.48m
- Gobert Sophie Retail sale of pharmaceutical products Bruges · balance sheet €2.48m
- Tamiphar Retail sale of pharmaceutical products Lasne · balance sheet €2.46m
- Abfab Retail sale of pharmaceutical products Anderlecht · balance sheet €2.46m
- De Witte - De Sutter Retail sale of pharmaceutical products Dendermonde · balance sheet €2.45m
- DE BIE T. Retail sale of pharmaceutical products Affligem · balance sheet €2.45m
- Holsbeek Brecht - Sint -Lenaerts Retail sale of pharmaceutical products Brecht · balance sheet €2.44m
Frequently asked questions about Pharmadefi
What is the revenue of Pharmadefi?
Pharmadefi files its accounts in a format where revenue is optional: it is not published for 2025.
What is the VAT number of Pharmadefi?
In Belgium, the VAT number is the company number prefixed with BE: BE0437576896 for Pharmadefi, if the company is VAT-registered. Its company number (CBE) is 0437.576.896.
Where is the registered office of Pharmadefi?
According to the CBE register, the registered office of Pharmadefi is in 6700 Arlon.
What is the equity of Pharmadefi?
At the close of the 2025 financial year, the equity of Pharmadefi amounts to 671,836 €, a solvency of 27.1% of total assets.
How many people work at Pharmadefi?
3.2 full-time equivalents on average according to the 2025 social balance sheet.
Who manages Pharmadefi?
The register lists 4 active mandates at Pharmadefi. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
The full file of Pharmadefi
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →